Oral semaglutide cut heavy drinking days in alcohol use disorder, but missed its primary endpoint

Design

Phase 2, double-blind, placebo-controlled randomised trial, 8 weeks

Population

50 treatment-seeking adults with moderate to severe alcohol use disorder

Primary outcome

Laboratory alcohol cue-induced craving at week 6

Effect

No difference in primary outcome; heavy drinking days reduced (b −0.58, 95% CI −1.01 to −0.15)

Fifty treatment-seeking adults with moderate to severe alcohol use disorder were randomised to oral semaglutide (3 mg daily for four weeks, then 7 mg for four weeks) or placebo in a double-blind phase 2 trial. The primary outcome was craving provoked by alcohol cues in the laboratory at week six.

Semaglutide did not reduce laboratory craving or drinks per day. It did reduce heavy drinking days, drinks per drinking day, everyday craving and alcohol-related consequences, and more participants on semaglutide dropped at least one WHO drinking-risk level. Cannabis use days also fell.

This is a small, short trial whose primary outcome was negative, so the positive findings are secondary. They are consistent with earlier work in less severe drinkers, which is why the authors call for larger trials. Semaglutide is not licensed for alcohol use disorder anywhere, and its cost and supply in India make off-label use for this purpose hard to justify. What changes in practice is narrower: patients already taking a GLP-1 drug for diabetes or weight may report drinking less, and that is worth asking about. It was published in July 2026.

• Do not prescribe semaglutide for alcohol use disorder outside a trial; it is unlicensed and the primary endpoint was negative.
• Ask patients already on a GLP-1 drug about any change in their drinking, and record it.
• Offer naltrexone or acamprosate first for patients who want medication.
• Watch for larger phase 3 trials before changing practice.

Why it matters

Patients are already asking for GLP-1 drugs for alcohol; this trial gives a measured answer.

Don't overread it

The heavy-drinking benefit is a secondary outcome in 50 people after a negative primary endpoint.

The statistics, in plain English

The trial's main question, laboratory craving, showed no difference. The benefits were in secondary outcomes, and when several secondary outcomes are tested some can reach significance by chance. Their confidence intervals end close to zero (for heavy drinking days, −1.01 to −0.15), so the true effect could be small.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.